<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2784">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04385186</url>
  </required_header>
  <id_info>
    <org_study_id>CT01</org_study_id>
    <nct_id>NCT04385186</nct_id>
  </id_info>
  <brief_title>Inactivated Convalescent Plasma as a Therapeutic Alternative in Patients CoViD-19</brief_title>
  <official_title>Inactivated Convalescent Plasma as a Therapeutic Alternative in Hospitalized Patients CoViD-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Blood Center Foundation, Hemolife</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Blood Center Foundation, Hemolife</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Convalescent plasma is a way to provide passive immunity to a person exposed to an infectious
      agent. It has been used as a therapeutic tool for emerging viral infections without specific
      treatment and with high morbidity and mortality, such as Influenza H1N1, H5N1, H7N9, Ebola,
      MERS, SARS-CoV1, and even SARS-Cov2, with satisfactory results regarding evolution clinic of
      patients treated and without significant adverse events reported. One of its main advantages
      of convalescent plasma is to generate a rapid immune response (even faster than a vaccine),
      against a pathogen that circulates in a specific geographic area, probably common for both
      donor and recipient.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study consists of obtaining convalescent plasma by means of apheresis, from recovered
      donors, who meet the eligibility criteria to donate. Then this plasma will be inactivated by
      riboflavin and UV based photochemical treatment (Mirasol technology - Terumo BCT®), in order
      to add more transfusion security to the procedure. Finally, it will be transfused to CoViD-19
      patients hospitalized in any of the participating clinics. There are currently no reported
      significant adverse events associated with this therapy. Have been published two serial cases
      reports,more evidence is necessary to standardize the treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 20, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>MULTICENTER, CONTROLLED, RANDOMIZED, SIMPLE BLIND, CLINICAL TRIAL</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mortality reduction in CoViD-19 patients treated with inactivated convalescent plasma + support treatment</measure>
    <time_frame>Over a period of 28 days</time_frame>
    <description>To assess the efficacy in reducing mortality in CoViD-19 patients treated with inactivated convalescent plasma together with the support treatment selected by the respective hospital</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical evolution</measure>
    <time_frame>Over a period of 28 days</time_frame>
    <description>Number of Participants with resolution of fever (&lt;38ºC temperature)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical evolution by seven-parameter ordinal scale</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>The clinical improvement will be established with a two-point improvement within this seven categories (recommended by World Organization Health-WHO): 1) Not hospitalized, with resumption of normal activities 2) Not hospitalized, but unable to resume normal activities 3) Hospitalized that does not require supplemental oxygen 4) Hospitalized requiring supplemental oxygen 5) Hospitalized requiring high-flow nasal oxygen therapy, non-invasive mechanical ventilation, or both 6) Hospitalized requiring extracorporeal membrane oxygenation, invasive mechanical ventilation, or both 7) death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multi-organ failure progression</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Evolution by SOFA (Sequential Organ Failure Assessment), The range is between 0 and 24 points, with the highest scores being indicators of a more serious illness</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin concentration</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Compare the change in hemoglobin concentration at 3, 7, 14 and 28 days after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood cell count</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Compare the change in blood cell count at 3, 7, 14 and 28 days after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum creatinine level</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Compare the change in Serum creatinine concentration at 3, 7, 14 and 28 days after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in aspartate aminotransferase level</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Compare the change in aspartate aminotransferase level at 3, 7, 14 and 28 days after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in alanin aminotransferase level</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Compare the change in Alanine aminotransferase levels at 3, 7, 14 and 28 days after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bilirubin level</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Compare the change in bilirubin levels at 3, 7, 14 and 28 days after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lactate dehydrogenase level</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Compare the change in lactate dehydrogenase levels at 3, 7, 14 and 28 days after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in creatine kinase level</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Compare the change in creatine kinase levels at 3, 7, 14 and 28 days after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in creatine kinase MB level</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Compare the change in creatine kinase MB levels at 3, 7, 14 and 28 days after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C reactive protein concentration</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Compare the change in C reactive protein concentration at 3, 7, 14 and 28 days after treatment, in mg/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in D Dimer concentration</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Compare the change in D Dimer concentration at 3, 7, 14 and 28 days after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Procalcitonin concentration</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Compare the change in procalcitonin concentration at 3, 7, 14 and 28 days after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in IL6 level</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Compare the change in IL6 level at 3, 7, 14 and 28 days after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiography imaging</measure>
    <time_frame>Over a period of 60 days</time_frame>
    <description>Resolution of chest radiography imaging findings (example, bilateral, peripheral and basal predominant ground-glass opacity, consolidation, or both)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tomography imaging</measure>
    <time_frame>Over a period of 60 days</time_frame>
    <description>Resolution of tomography imaging (example, patches located in the subpleural regions of the lung)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of oxygenation</measure>
    <time_frame>3, 7, 14 and 28 days</time_frame>
    <description>Arterial oxygen partial pressure (PaO2) in mmHg / Inspired fraction of oxygen (FIO2) ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Load</measure>
    <time_frame>0, 3, 7 days and until hospital discharge or a maximum of 60 days whichever comes first</time_frame>
    <description>Viral Load Quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibody titer</measure>
    <time_frame>Day 0, Day 3 and Day 7</time_frame>
    <description>Neutralizing antibody anti SARS-CoV-2 titer evolution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen-free days through Day 60</measure>
    <time_frame>Until hospital discharge or a maximum of 60 days whichever comes first</time_frame>
    <description>Number of days without use of Oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation-free days through Day 28</measure>
    <time_frame>Until hospital discharge or a maximum of 28 days whichever comes first</time_frame>
    <description>Number of days without use of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care Unit (ICU)-free days through Day 28</measure>
    <time_frame>Until hospital discharge or a maximum of 28 days whichever comes first</time_frame>
    <description>Time outside of ICU, in days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital-free days through Day 60</measure>
    <time_frame>Until hospital discharge or a maximum of 60 days whichever comes first</time_frame>
    <description>Time outside of the hospital, in days</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 28 days</time_frame>
    <description>Occurrence of adverse events during inactivated convalescent plasma transfusion, classified according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Infections, Coronavirus</condition>
  <arm_group>
    <arm_group_label>Convalescent plasma+Support treatment selected by the hospital</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive two doses of ABO - Rh compatible inactivated convalescent plasma, each one of 200 mililiters (mL), with a 24-hour interval via transfusion, for a final volume of 400 mL, meanwhile they continue to receive the supportive treatment chosen by the hospitals, according to each institutional protocol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Support treatment selected by the hospital</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The best support treatment selected by the hospital, according to each institutional protocol. Due to the ongoing development of knowledge of pathophysiology and scientific evidence of the available alternatives, it will be selected at the time of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Inactivated convalescent plasma</intervention_name>
    <description>Day 0: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma, Start of support treatment selected by medical staff according to each institutional protocol
Day 1: Transfusion of 200mL of ABO -Rh compatible inactivated convalescent plasma</description>
    <arm_group_label>Convalescent plasma+Support treatment selected by the hospital</arm_group_label>
    <other_name>Inactivated convalescent plasma SARS-Cov-2 + Support treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Support treatment</intervention_name>
    <description>Day 0: Start of support treatment selected by medical staff according to each each institutional protocol</description>
    <arm_group_label>Convalescent plasma+Support treatment selected by the hospital</arm_group_label>
    <arm_group_label>Support treatment selected by the hospital</arm_group_label>
    <other_name>Support treatment under medical decision</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Over 18 years old

          -  Confirmed laboratory diagnosis for qRT-PCR to SARS-CoV-2

          -  Meet any of the following medical criteria (Defined by WHO): Be currently hospitalized
             with: Pneumonia, Severe pneumonia, Acute Respiratory Distress Syndrome (moderate or
             severe), Sepsis or Septic shock

          -  The patient, or his representative, must sign an informed consent

        Exclusion Criteria:

          -  Participate in another clinical trial for CoViD- 19

          -  History of acute allergic transfusion reactions due to transfusion of blood or other
             components, especially plasma components (fresh frozen plasma, cryoprecipitate and
             platelets),

          -  History of allergic reaction due to IgA deficiency

          -  Allergic reaction to sodium citrate or riboflavin (vitamin B2)

          -  History of immunosuppression
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrés F Zuluaga, MD, MSc, MeH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Antioquia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrés F Zuluaga, MD, MSc, MeH</last_name>
    <phone>3014020291</phone>
    <email>andres.zuluaga@udea.edu.co</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ana L Muñoz, MSc, PhD</last_name>
    <email>ana.munoz@hemolifeamerica.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clínica Antioquía</name>
      <address>
        <city>Medellín</city>
        <state>Antioquía</state>
        <zip>0500</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Diego Gómez, MD. MSc</last_name>
      <email>diego.gomez@clinicanuestra.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Sagrado Corazón</name>
      <address>
        <city>Medellín</city>
        <state>Antioquía</state>
        <zip>0500</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IPS Universitaria</name>
      <address>
        <city>Medellín</city>
        <state>Antioquía</state>
        <zip>0500</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad de Antioquía</name>
      <address>
        <city>Medellín</city>
        <state>Antioquía</state>
        <zip>0500</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Andrés F Zuluaga, MD, MSc, MeH</last_name>
      <phone>3014020291</phone>
      <email>andres.zuluaga@udea.edu.co</email>
    </contact>
    <investigator>
      <last_name>Amanda E Maestre, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Blood Center Foundation, Hemolife/Fundación Banco Nacional de Sangre Hemolife</name>
      <address>
        <city>Bogotá</city>
        <state>Cundinamarca</state>
        <zip>1101</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Ana L Muñoz, MSc, PhD</last_name>
      <phone>+573128879089</phone>
      <email>ana.munoz@hemolifeamerica.org</email>
    </contact>
    <investigator>
      <last_name>Ana L Muñoz, MSc, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miguel G Rueda, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos A Arbelaez, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabian H Muñoz, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica Rosales</name>
      <address>
        <city>Pereira</city>
        <state>Risaralda</state>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Diego Gómez, MD, MSc</last_name>
      <email>diego.gomez@clinicanuestra.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinica Nuestra</name>
      <address>
        <city>Cali</city>
        <state>Valle</state>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Diego Gómez, MD, Msc</last_name>
      <email>diego.gomez@clinicanuestra.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clínica Corpas</name>
      <address>
        <city>Bogotá</city>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>E.S.E Hospital San Rafael Facatativa</name>
      <address>
        <city>Facatativa</city>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Fernando J Charries, MD, MSc</last_name>
    </contact>
    <investigator>
      <last_name>José R Almarales, MD, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clínica la Estancia</name>
      <address>
        <city>Popayán</city>
        <country>Colombia</country>
      </address>
    </facility>
    <contact>
      <last_name>Diego Gómez, MD, MSc</last_name>
      <email>diego.gomez@clinicanuestra.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Colombia</country>
  </location_countries>
  <link>
    <url>https://iris.paho.org/handle/10665.2/52036</url>
    <description>Regulatory considerations for the use of convalescent plasma to CoViD-19 emergency</description>
  </link>
  <reference>
    <citation>Epstein J, Burnouf T. Points to consider in the preparation and transfusion of COVID-19 convalescent plasma. Vox Sang. 2020 Apr 22. doi: 10.1111/vox.12939. [Epub ahead of print]</citation>
    <PMID>32319102</PMID>
  </reference>
  <reference>
    <citation>Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, Wei J, Xiao H, Yang Y, Qu J, Qing L, Chen L, Xu Z, Peng L, Li Y, Zheng H, Chen F, Huang K, Jiang Y, Liu D, Zhang Z, Liu Y, Liu L. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Apr 28;323(16):1582-1589. doi: 10.1001/jama.2020.4783.</citation>
    <PMID>32219428</PMID>
  </reference>
  <reference>
    <citation>Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003.</citation>
    <PMID>32167489</PMID>
  </reference>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 6, 2020</study_first_submitted>
  <study_first_submitted_qc>May 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 12, 2020</study_first_posted>
  <last_update_submitted>May 30, 2020</last_update_submitted>
  <last_update_submitted_qc>May 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CoViD-19</keyword>
  <keyword>Pathogen inactivation</keyword>
  <keyword>Apheresis</keyword>
  <keyword>Convalescent plasma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

